How should lamivudine (3TC) be dosed in patients with chronic kidney disease based on their creatinine clearance/eGFR?

Lamivudine Dosing in Chronic Kidney Disease

Lamivudine requires dose adjustment based on creatinine clearance in patients with CKD, with specific reductions starting at CrCl <50 mL/min. 1

Dosing Algorithm by Creatinine Clearance

For HIV treatment (standard 300 mg daily dose in normal renal function):

• CrCl ≥50 mL/min: No adjustment needed - 150 mg twice daily OR 300 mg once daily 2, 1

• CrCl 30-49 mL/min: 150 mg once daily 2, 1

• CrCl 15-29 mL/min: 150 mg loading dose, then 100 mg once daily 2, 1

• CrCl 5-14 mL/min: 150 mg loading dose, then 50 mg once daily 2, 1

• CrCl <5 mL/min: 50 mg loading dose, then 25 mg once daily 2, 1

• Hemodialysis: 50 mg loading dose, then 25 mg once daily (no supplemental dose needed after dialysis) 2, 1

• Peritoneal dialysis: 50 mg loading dose, then 25 mg once daily 2, 1

For Hepatitis B treatment (standard 100 mg daily dose in normal renal function):

• CrCl ≥50 mL/min: 100 mg once daily 3, 4

• CrCl 30-49 mL/min: 100 mg loading dose, then 50 mg once daily 3, 4

• CrCl 15-29 mL/min: 100 mg loading dose, then 25 mg once daily (or 35 mg loading dose, then 25 mg once daily per some guidelines) 3, 4

• CrCl 5-14 mL/min: 35 mg loading dose, then 15 mg once daily 3, 4

• CrCl <5 mL/min: 35 mg loading dose, then 10 mg once daily 3, 4

Key Clinical Considerations

Dialysis timing: No additional dosing is required after routine 4-hour hemodialysis sessions. The daily maintenance dose can be given at any time, not necessarily post-dialysis. 1

Pediatric patients: Insufficient data exist for specific pediatric dose adjustments in renal impairment. Consider reducing the dose and/or increasing the dosing interval based on the degree of renal dysfunction. 1

Combination products: Fixed-dose combinations containing lamivudine (e.g., Combivir, Trizivir, Epzicom) should NOT be used in patients with CrCl <50 mL/min. Instead, administer the individual component medications with appropriate dose adjustments. 2

Monitoring: The evidence carries a B-I rating (good evidence, strong recommendation) for these dose adjustments in HIV treatment, reflecting well-established pharmacokinetic data supporting these recommendations. 2

Lactic acidosis concern: Nucleoside analogues should NOT be withheld in patients with reduced renal function due to fear of lactic acidosis - this concern is not supported by evidence and dose adjustment is the appropriate management strategy. 2